Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans

Front Endocrinol (Lausanne). 2023 Aug 7:14:1253675. doi: 10.3389/fendo.2023.1253675. eCollection 2023.

A L De Sousa-Coelho^{1

2

3}, R Rodriguez-Rodriguez^{4

5}, S Softic⁶, J W Jonker⁷, J Relat^{5

8

9}

¹ Escola Superior de Saúde (ESS), Universidade do Algarve (UAlg), Faro, Portugal.
² Algarve Biomedical Center Research Institute (ABC-RI), Universidade do Algarve (UAlg), Faro, Portugal.
³ Algarve Biomedical Center (ABC), Faro, Portugal.
⁴ Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya, Barcelona, Spain.
⁵ Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
⁶ Department of Pediatrics, Division of Pediatric Gastroenterology, Kentucky Children's Hospital, and Department of Pharmacology and Nutritional Sciences, University of Kentucky College of Medicine, Lexington, KY, United States.
⁷ Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
⁸ Department of Nutrition, Food Sciences and Gastronomy, School of Pharmacy and Food Sciences, University of Barcelona, Santa Coloma de Gramenet, Spain.
⁹ Institute of Nutrition and Food Safety of the University of Barcelona (INSA-UB), Santa Coloma de Gramenet, Spain.

No abstract available

Keywords: FGF21 (fibroblast growth factor 21); beta-Klotho; insulin resistance; metabolism; obesity.

Publication types